Initiation criteria: For the treatment of adult patients with severe alopecia areata (AA) who meet the following criteria: 1. Have a Severity of Alopecia Tool (SALT) score of 50 or above, and 2. Have experienced the current episode of AA for more than 6 months but less than 8 years. The maximum duration of initial authorization is 36 weeks. Renewal criteria: For continuation of reimbursement, the patient must demonstrate beneficial clinical effect, defined as achieving a SALT score of 20 or less at 36 weeks after treatment initiation. Maintenance of a SALT score of 20 or less every 12 months thereafter is required for reimbursement renewal. Dosing and prescribing: The recommended dose is 2mg once daily. The maximum funded dose is 4mg once daily. Baricitinib should be prescribed by a dermatologist with expertise managing patients with severe AA. Baricitinib should not be used in combination with other JAK inhibitors, biologic immunomodulators, or systemic immunosuppressants.